Additional Efficacy Findings from the LIBERTY-AD Four-Year Open-Label Extension Study
January 26th 2023Continuing their discussion about efficacy, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review long-term results on pruritus. Additionally, they explore data for patients who switched from weekly to every-other-week dupilumab treatment.